Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Jinghua Weikang Jiaowan is a traditional Chinese medicine formulation used primarily for gastrointestinal disorders. It contains the herbal ingredients Schizonepeta tenuifolia (土荆芥) and Inula britannica (水团花). The product is indicated for symptoms such as epigastric distension and pain, belching, acid regurgitation, gastric discomfort, and bitter taste in the mouth caused by a combination of cold and heat syndromes with qi stagnation and blood stasis. Pharmacological studies indicate that it can inhibit Helicobacter pylori growth, reduce gastric acid secretion, suppress pepsin activity, protect the gastric mucosa, promote ulcer healing, relieve pain through promoting blood circulation and removing stasis, disperse cold to regulate qi flow in the stomach and intestines. It is commonly used for gastritis or peptic ulcer patients presenting with these traditional symptom patterns[1][2][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on jinghua weikang jiaowan.